Delivery of short chain fatty acid butyrate to overcome Fusobacterium nucleatum-induced chemoresistance
Journal of Controlled Release · 2023-11 · 363 · 43-56
DOI: 10.1016/j.jconrel.2023.09.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023-11. Verfasst von Linfu Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, S…. Hauptthemen laut MEDLINE: Fusobacterium Infections, Colorectal Neoplasms. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Ministry of Education of the People's Republic of China.
Abstract (Originalsprache)
The gut microbiota is closely associated with the progression of colorectal cancer (CRC) in which Fusobacterium nucleatum (F. nucleatum) was found to induce cancer resistance to chemotherapeutics. To relieve F. nucleatum-induced drug resistance, herein, we found that short-chain fatty acid butyrate can inhibit the growth, enrichment and adhesion of F. nucleatum in colorectal cancer tissues by downregulating the expression of adhesion-associated outer membrane proteins, including RadD, FomA, and FadA, to reduce the colonization and invasion of F. nucleatum and relieve the chemoresistance induced by F. nucleatum. Leveraging the killing effect of butyrate on F. nucleatum, sodium butyrate (NaBu) was encapsulated in liposomes or prepared as NaBu tablets with Eudragit S100 coating and administered by intravenous injection or oral administration, respectively. Interestingly, both intravenous administration of NaBu liposomes and oral delivery of NaBu tablets could effectively inhibit the proliferation of F. nucleatum and significantly improve the therapeutic efficacy of oxaliplatin in mice with subcutaneous colorectal tumors, orthotopic colorectal tumors and even spontaneously formed colorectal tumors. Thus, our work provides a simple but effective formulation of NaBu to relieve F. nucleatum-induced chemoresistance, exhibiting ideal clinical application prospects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou 215123, PR China.
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, PR China.
- Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou 215123, PR China. Electronic address: chenqian@suda.edu.cn.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Ministry of Education of the People's Republic of China
- Collaborative Innovation Center of Suzhou Nano Science and Technology
Zitieren
APA
Chen, L., Zhao, R., Kang, Z., Cao, Z., Liu, N., Shen, J., Wang, C., Pan, F., Zhou, X., Liu, Z., Yang, Y., & Chen, Q. (2023). Delivery of short chain fatty acid butyrate to overcome Fusobacterium nucleatum-induced chemoresistance. Journal of Controlled Release, 363, 43-56. https://doi.org/10.1016/j.jconrel.2023.09.028
Vancouver
Chen L, Zhao R, Kang Z, Cao Z, Liu N, Shen J, et al. Delivery of short chain fatty acid butyrate to overcome Fusobacterium nucleatum-induced chemoresistance. Journal of Controlled Release. 2023;363:43-56. doi:10.1016/j.jconrel.2023.09.028
BibTeX
@article{Chen2023,
author = {Chen, Linfu and Zhao, Rui and Kang, Zheyu and Cao, Zhiqin and Liu, Nanhui and Shen, Jingjing and Wang, Cheng and Pan, Feng and Zhou, Xiao and Liu, Zhuang and Yang, Yang and Chen, Qian},
title = {Delivery of short chain fatty acid butyrate to overcome Fusobacterium nucleatum-induced chemoresistance},
journal = {Journal of Controlled Release},
year = {2023},
volume = {363},
pages = {43--56},
doi = {10.1016/j.jconrel.2023.09.028}
}
EUVIMED